Talaris Therapeutics
Cell Processing Facility & Corporate Office
570 S. Preston St.
Louisville, KY 40202
United States
Website: https://talaristx.com/
Email: info@talaristx.com
About Talaris Therapeutics
Talaris Therapeutics is developing a breakthrough, one-time cell therapy to enable patients who receive a living donor kidney transplant to no longer require lifelong immunosuppression, without rejecting their donated organ.
Achieving durable, drug-free immune tolerance to a donated organ has been referred to as a “Holy Grail” of organ transplant. In a ground-breaking, phase 2 study conducted between 2008 - 2016, our lead therapy, FCR001, enabled 70% of patients to be weaned off all immunosuppression within 12 months of their kidney transplant. No tolerized patient has had to resume immunosuppression. We have followed these patients for an average of almost five years since their transplant, and the longest for over ten years. Our single-dose cell therapy has also shown the potential to induce durable remission of certain types of severe auto-immune diseases, and to benefit other solid organ transplant patients. Talaris has announced a $100M private financing from leading life sciences investors and has initiated a Phase 3 pivotal trial of our therapy in living donor kidney transplant patients. We also expect to initiate two Phase 2 trials of our therapy in additional indications in 2020. Our cell processing facility and most of our operations are based in Louisville, KY, and we also have a corporate office in Boston, MA.
23 articles with Talaris Therapeutics
-
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
6/14/2021
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three-month period ended March 31, 2021,
-
Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
6/3/2021
Talaris Therapeutics, Inc. announced upcoming presentations of data from the company’s Phase 2 study of FCR001 at the American Transplant Congress taking place virtually June 4-9, 2021.
-
There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.
-
Talaris Therapeutics Announces Closing of Initial Public Offering
5/11/2021
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share.
-
Talaris Therapeutics Announces Pricing of Initial Public Offering
5/7/2021
Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, announced the pricing of its initial public offering of 8,825,000 shares of common stock at a price to the public of $17.00 per share.
-
Money on the Move: April 29 – May 4
5/5/2021
April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world. -
Two weeks after announcing plans for initial public offerings, Gyroscope Therapeutics and Talaris Therapeutics have now set the terms for their debut on the Nasdaq.
-
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.
-
It didn’t take long for Jason Campagna to find a new role after departing Intercept Pharmaceuticals last month. Campagna will take on the role of chief medical officer for Q32 Bio.
-
Talaris Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer
3/4/2021
Talaris Therapeutics, Inc., a late- clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune or metabolic disorders, today announced the appointment of Mary Kay Fenton as Chief Financial Officer.
-
Talaris Therapeutics Appoints Four Vice Presidents in Areas of Strategic Importance
2/25/2021
Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune, or metabolic disorders, today announced the appointment of four vice presidents in areas of strategic importance for the company.
-
Talaris Therapeutics Adds Two Experienced Biotechnology Executives to its Board of Directors
1/20/2021
Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the appointment of Sapna Srivastava, Ph.D., and Gaurav Shah, M.D.,
-
Talaris Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/8/2021
Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, is scheduled to virtually present at the 39th Annual J.P. Morgan Healthcare Conference
-
BioSpace Movers & Shakers, November 13
11/13/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Talaris Therapeutics Expands Leadership Team With Appointments of Accomplished Executives in Manufacturing, Portfolio Strategy and Clinical Operations
11/12/2020
Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the expansion of its senior leadership team with the appointments of Michael Zdanowski as Chief Technology Officer, Farah Natoli as Head of Portfolio and Program Management and Mary West as Vice
-
Does Talaris’ Investigational Cell Therapy Have Potential to Be a ‘Pipeline in a Product’?
11/10/2020
Talaris Chief Executive Officer Scott Requadt sees FCR001, the company’s investigational cell therapy, as a potential pipeline in a product (an experimental treatment that could have multiple uses across a number of indications). -
Talaris Therapeutics Closes $115 Million Series B Financing
10/6/2020
Proceeds to support ongoing Phase 3 registration trial of Talaris’ lead product candidate FCR001 in living donor kidney transplant, and additional Phase 2 trials next year in autoimmune disease and organ transplant
-
Talaris Therapeutics Announces Collaboration With Kentucky Organ Donor Affiliates to Advance Preclinical Study of Tolerance Induction to Organs From Deceased Donors
9/14/2020
Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced a collaboration with Kentucky Organ Donor Affiliates (KODA). KODA is an independent, non-profit organ and tissue procurement organization that facilitates deceased donor transplants throughout K
-
Talaris Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
7/22/2020
Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced that the first patient has been dosed in the FREEDOM-1 Phase 3 clinical trial of FCR001 in living donor kid
-
FDA Approves Talaris Therapeutics’ IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma
7/8/2020
Talaris Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug application for the evaluation of Talaris’ novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis, a severe form of the rare autoimmune disease scleroderma.